Cargando…
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma
Ovarian serous cystadenocarcinoma is a common malignant tumor of female genital organs. Treatment is generally less effective as patients are usually diagnosed in the late stage. Therefore, a well-designed prognostic marker provides valuable data for optimizing therapy. In this study, we analyzed 30...
Autores principales: | Liu, Li-Wei, Zhang, Qiuhao, Guo, Wenna, Qian, Kun, Wang, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949334/ https://www.ncbi.nlm.nih.gov/pubmed/27478834 http://dx.doi.org/10.1155/2016/6945304 |
Ejemplares similares
-
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
por: Guo, Wenna, et al.
Publicado: (2018) -
An Immune-Related Gene-Based Signature as Prognostic Tool in Ovarian Serous Cystadenocarcinoma
por: Shi, Fengjuan, et al.
Publicado: (2021) -
Gastric metastasis of ovarian serous cystadenocarcinoma
por: Yang, Shiqiang
Publicado: (2018) -
Stem Cell-Associated Signatures Help to Predict Diagnosis and Prognosis in Ovarian Serous Cystadenocarcinoma
por: Li, Li, et al.
Publicado: (2023) -
Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma
por: Zhang, Jue, et al.
Publicado: (2018)